Announcements Trials

Conditions

Dermatologic 1

Drug Classes

Anti-PD-1 12BRAF inhibitor 4MEK inhibitor 3Anti-PD-L1 2Anti-HER2 ADC 1Bispecific gp100 peptide-HLA-directed CD3 T-cell engager 1Mononuclear cell vaccine 1Multi-ingredient 1Nitrogen mustard 1RET inhibitor 1ROS1 inhibitor 1TRK inhibitor 1
Bispecific gp100 peptide-HLA-directed CD3 T-cell engager × Dermatologic × Clear all

1 Announcement

2022-01-25

FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma

Drug
Kimmtrak (tebentafusp-tebn) · Bispecific gp100 peptide-HLA-directed CD3 T-cell engager
Condition
Dermatologic
Data powered by HemOnc (CC BY 4.0) Colophon âš¡